Igenomix portfolio includes pioneering genetic tests to help reproductive-health professionals to analyse and treat their patients before, during and after their reproductive journey.
Vitrolife delivers innovative, high-quality products to ensure optimal care at every stage of the IVF journey, from error prevention and gamete handling to embryo evaluation and cryopreservation.
Did you miss our live Studio at ESHRE?
Vitrolife Group Academy Studio
Watch the presentations and demonstrations from our Studio.
Latest financial report
Interim report Q2, 2025: Strong performance across Consumables
Sales was +3% in local currencies excluding discontinued business, 0% in local currencies. Total sales amounted to 871 MSEK (941), significantly impacted by currency. Despite economic uncertainties we have remained resilient delivering growth by taking share.
Press Releases
Financial Calendar
-
23 Oct 2025
Interim report Q3, 2025
-
03 Feb 2026
Fourth quarter and full year report 2025
-
23 Apr 2026
Interim report Q1, 2026
Careers
The Vitrolife Group offers an attractive workplace with an opportunity to work for a higher purpose, a purpose that makes a difference in people’s lives worldwide.
Investor relations
Our aim is to have a strong capital base to enable continued high growth, both organically and through acquisitions. We strive to achieve growth through profitability.
Sustainability
Ensuring sustainability in everything we do is one of our key strategic priorities. Learn more on our approach and sustainability themes.